Neurogene Inc reports a Return on Equity (ROE) of -41.48%.

What is NGNE's dividend yield?

Neurogene Inc offers a dividend yield of 0.00%.

What is NGNE's Quality Score?

Our AI rates NGNE's overall financial quality at 0 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy NGNE?

Our AI Timing Score for NGNE is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does NGNE belong to?

Neurogene Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Neurogene Inc (NGNE) Stock Price, Quality Score & AI Analysis

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

NGNE AI Analysis Summary

Our AI summary for NGNE: Neurogene Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -41.48%, a dividend yield of 0.00%. Its financial Quality Score stands at 0/100 — fundamentals below the market average. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

NGNE

Neurogene Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 89

USD 34.41

1.54 (4.69%) Day Change

Watchlist Portfolio Compare Chart

0.01

D/E

-41.5%

ROE

-37.5%

ROA

0.00%

Div Yield

NEUROGENE INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 34.41 Price 1.54 (4.69%) Day Change	NEWS SCORE: 89

NGNE, the overall quality is not good ( Quality = 0) and the timing to buy is ...(Sign In to See)...

Loading chart...

0 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	89
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	34.41
PBV / Sector	2.76 / 44,022.72
Earning Per Share	-5.18

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	8.34 M
Average 1W Daily Value	4.59 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

43%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.24
NPM Average (%) / Sector	-8,123.68 / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-37.48 / 185,260.96
ROA Average (%) / Sector	-31.60 / 36,684.70
ROA Change Average (%) / Sector	7.27 / 422,221.66
ROE (%) / Sector	-41.48 / 243,762.23
ROE Average (%) / Sector	-35.06 / 48,758.47
ROE Change Average (%) / Sector	5.35 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:35
Symbol	NGNE
Name	NEUROGENE INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	19.95 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	655.77 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 535 W 24th Street, New York, NY, United States, 10011

Phone: 855 508 3568

Website: https://www.neurogene.com

Employees: 131

Sector: Healthcare >> Biotechnology

Description: Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.